Hangzhou Tigermed Consulting Co., Ltd. (Tigermed) disclosed that it repurchased 1,550,700 A-shares on 10 June 2026 via the Shenzhen Stock Exchange. The buyback was executed at prices ranging from RMB 38.22 to RMB 39.50 per share, with a volume-weighted average price of RMB 38.74, for a total consideration of RMB 60.07 million.
Following the transaction, the number of issued shares (excluding treasury shares) fell by 0.21% to 730.47 million. Treasury shares increased to 7.43 million, while total issued shares remained unchanged at 737.90 million.
All repurchased shares are being held as treasury shares; none have been cancelled to date. The company confirmed that the operation complied with the rules of both the Hong Kong Stock Exchange and the Shenzhen Stock Exchange.
Comments